K-numberK241923
Device nameEFAI Neurosuite CT Midline Shift Assessment System (MLS-CT-100)
ApplicantEver Fortune.Ai, Co., Ltd.
Product codeQAS
Device classClass II
Decision dateDec 6, 2024
DecisionSubstantially Equivalent
Regulation892.2080
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

EFAI MLSCT is a software tool that analyzes non-contrast head CT scans using deep learning to automatically identify cases with suspected midline shift (MLS). It provides case-level notifications to radiologists through PACS/workstation to help prioritize clinical review, without marking specific image locations or replacing standard clinical assessment.

Technological characteristics

Both the proposed device and predicate use artificial intelligence algorithms with image databases to analyze non-contrast head CTs. Key differences: proposed device detects only midline shift with no user configuration options, whereas predicate detects four findings (ICH, mass effect, MLS, cranial fracture) with user controls. Proposed device does not provide preview images; predicate does. Proposed device deploys only on-premise; predicate can deploy on-premise or cloud with HIPAA-compliant interfaces.

Test standards cited

IEC 62304:2006/A1:2016 (Medical device software – Software life cycle processes); ISO 14971:2019 (Application of risk management to medical devices); FDA guidance documents on Device Software Functions and Cybersecurity in Medical Devices.

Substantial equivalence argument

The proposed device and predicate both provide case-level triage notifications for non-contrast head CT using AI algorithms to flag suspected pathologies without altering original images or providing diagnostic segmentation. Although the proposed device focuses exclusively on midline shift without user configuration and the predicate covers four findings with configurable triage, this narrower scope does not raise new safety or effectiveness questions because both devices operate identically in workflow—as passive notifications alongside standard clinical interpretation. The proposed device's clinical validation demonstrated sensitivity 0.961 and specificity 0.955 (substantially equivalent to predicate's performance), and both use identical underlying technology. The on-premise-only deployment of the proposed device poses no new risks compared to the predicate's cloud option, since both present the same notifications to clinicians who retain full responsibility for image review.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →